Dr. M. Maral Mouradian is an internationally recognized physician-scientist trained in both clinical neuropharmacology at NINDS and in molecular biology under the tutelage of the Nobel laureate Marshall Nirenberg at NHLBI. Before assuming her current posts at Rutgers, she directed the Genetic Pharmacology group of NINDS conducting translational research in neurodegenerative disorders. Her contributions to Parkinson’s disease include seminal research providing the rationale for continuous dopaminergic drug delivery to mitigate the motor complications of L-Dopa, elucidation of molecular pathogenetic mechanisms of neurodegeneration and identification of new therapeutic targets and agents. To date, she has authored over 230 scholarly publications. Dr. Mouradian is the editor-in-chief of the journal Neurotherapeutics and directs the American Parkinson Disease Association (APDA) Center for Advanced Research at Robert Wood Johnson Medical School. Among her honors are the NIH Award of Merit and election to the Association of American Physicians.
Developing an Inhibitor of Transglutaminase 2 as a Disease-modifying Treatment for Parkinson’s Disease
Transglutaminase 2 Inhibitors as a Disease-Modifying Treatment for Parkinson's Disease
Validation of a Protein, Transglutaminase 2, as a Way to Reduce Alpha-synuclein Clumping and Toxicity in Parkinson's Disease